Breckenridge Pharmaceutical has entered into a multi-product agreement with Sam Chun Dang Pharm (SCD), based in Seoul, Korea, under which Breckenridge and SCD expect to develop and commercialize at least seven ANDAs. SCD will develop, manufacture and supply the products exclusively for Breckenridge for the U.S. market and Breckenridge will market and distribute the products in its label. This multi-product agreement represents the first foray for both companies having products developed and manu...